The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

Biocon Biologics has become the first biosimilar insulins company to partner with the International Diabetes Federation to help increase affordable access to insulin worldwide. The partnership was sealed at the start of centenary celebrations of the discovery of insulin. 

Biocon and Viatris have landed their second biosimilar insulin approval in Europe, for a rival to Novo Nordisk’s NovoRapid (insulin aspart). Analyst reaction was lukewarm considering the “disappointing” launch of insulin glargine in Europe more than two years ago.

From biomarkers to treatment effect size, agency officials respond to some of more than a hundred questions that poured in during a webinar on development of drugs to treat the liver disease.